For a breastfeeding adult on olanzapine 10 mg daily, fluoxetine 40 mg daily, and hydroxyzine 10 mg twice daily, should olanzapine be stopped and fluoxetine be reduced or tapered?

Management of Psychotropic Medications in a Breastfeeding Patient

Do not stop olanzapine or reduce fluoxetine based solely on breastfeeding status. Both medications can be continued during lactation with appropriate infant monitoring, as the benefits of treating maternal psychiatric illness typically outweigh the minimal risks to the breastfed infant.

Rationale for Continuing Current Regimen

Olanzapine During Breastfeeding

Olanzapine is acceptable for use during breastfeeding based on available evidence:

• Minimal infant exposure: The relative infant dose is only 0.3% of the weight-adjusted maternal dose, with milk-plasma ratios around 0.5 1
• Undetectable infant plasma levels: In most cases, olanzapine concentrations in infant plasma are below detection limits (<5 ng/mL) 1
• No adverse long-term outcomes: A prospective controlled study of 22 breastfeeding mothers on olanzapine found no increase in adverse outcomes compared to controls, though early discontinuation of breastfeeding was slightly more common 2
• Safety surveillance data: Analysis of 102 pregnancies with olanzapine during breastfeeding showed the majority (82.3%) reported no adverse events. The most common reported events were somnolence (3.9%), irritability (2%), tremor (2%), and insomnia (2%) 3

Olanzapine is categorized as acceptable for breastfeeding in expert reviews 4.

Fluoxetine During Breastfeeding

Fluoxetine at 40 mg daily can be continued during breastfeeding:

• Minimal platelet serotonin transporter blockade: A study of 11 breastfeeding mother-infant pairs showed that 10 of 11 infants experienced no meaningful changes in platelet serotonin levels (a marker of central serotonin transporter blockade) while mothers took 20-40 mg fluoxetine daily 5
• Generally low infant plasma levels: Most breastfed infants have minimal to undetectable fluoxetine levels, though the long half-life of fluoxetine and its active metabolite norfluoxetine means some accumulation is possible
• Guideline support: The AAP guideline notes that mothers on SSRIs who desire to breastfeed should be counseled about risks and benefits, but does not recommend routine discontinuation 6

The FDA label for fluoxetine acknowledges its presence in breast milk but does not contraindicate breastfeeding 7.

Hydroxyzine

While the provided evidence doesn't specifically address hydroxyzine during breastfeeding, first-generation antihistamines are generally considered compatible with breastfeeding when used at standard doses.

Clinical Monitoring Plan

Instead of stopping medications, implement close infant monitoring:

1. Watch for sedation: Monitor for excessive drowsiness, poor feeding, or decreased responsiveness
2. Assess developmental milestones: Track normal infant development at routine pediatric visits
3. Monitor weight gain: Ensure adequate infant weight gain and growth
4. Observe for irritability or sleep disturbances: Though uncommon, these may indicate drug effects

Critical Caveats

• One infant in the fluoxetine study had measurable plasma drug levels and a substantial decline in platelet serotonin (to 40% of baseline), though without clinical adverse effects 5. This infant was exclusively breastfed and the mother had high plasma drug levels, suggesting that exclusive breastfeeding with higher maternal doses may increase risk.

• Early breastfeeding discontinuation was more common in the olanzapine-exposed group (5 of 22 vs. 0 of 51 controls, p=0.02) 2, possibly due to maternal concerns or subtle infant effects.

• Neonatal withdrawal symptoms were seen in 10% of infants exposed to olanzapine in utero 2, but this is distinct from breastfeeding exposure.

Risk-Benefit Analysis

Stopping or reducing these medications poses significant risks:

• Maternal psychiatric decompensation could severely impair mother-infant bonding and caregiving
• Untreated maternal mental illness has documented adverse effects on infant development
• The combination of olanzapine and fluoxetine suggests treatment-resistant depression, making medication discontinuation particularly risky

The infant exposure through breast milk is minimal compared to the therapeutic benefit for the mother, and no consistent pattern of serious adverse infant outcomes has been documented with either medication during breastfeeding.

Alternative Considerations Only If Necessary

If there are specific concerns about the current regimen (e.g., infant sedation, poor feeding), consider:

• Timing feeds: Breastfeed just before taking medications to minimize infant exposure at peak maternal drug levels
• Partial formula supplementation: Reduce but don't eliminate breastfeeding if concerns arise
• Switch SSRIs: Sertraline or paroxetine have lower infant plasma levels than fluoxetine, though this requires weighing the risk of maternal relapse during medication transition

Do not make changes based solely on breastfeeding status without clinical indication.